ACCESSION: MSBNK-Keio_Univ-KO002828
RECORD_TITLE: Eserine; LC-ESI-QQ; MS2; CE:40 V; [M+H]+
DATE: 2016.01.19 (Created 2007.07.07, modified 2011.05.10)
AUTHORS: Kakazu Y, Horai H, Institute for Advanced Biosciences, Keio Univ.
LICENSE: CC BY-NC-SA
COMMENT: KEIO_ID E007
CH$NAME: Eserine
CH$NAME: Physostigmine
CH$COMPOUND_CLASS: N/A
CH$FORMULA: C15H21N3O2
CH$EXACT_MASS: 275.16338
CH$SMILES: CNC(=O)Oc(c3)cc(c(c3)1)C(C)(C2)C(N(C)C2)N(C)1
CH$IUPAC: InChI=1S/C15H21N3O2/c1-15-7-8-17(3)13(15)18(4)12-6-5-10(9-11(12)15)20-14(19)16-2/h5-6,9,13H,7-8H2,1-4H3,(H,16,19)/t13-,15+/m1/s1
CH$LINK: CAS 57-47-6
CH$LINK: KEGG C06535
CH$LINK: NIKKAJI J4.579I
CH$LINK: PUBCHEM SID:8765
CH$LINK: INCHIKEY PIJVFDBKTWXHHD-HIFRSBDPSA-N
CH$LINK: COMPTOX DTXSID3023471
AC$INSTRUMENT: API3000, Applied Biosystems
AC$INSTRUMENT_TYPE: LC-ESI-QQ
AC$MASS_SPECTROMETRY: MS_TYPE MS2
AC$MASS_SPECTROMETRY: ION_MODE POSITIVE
AC$MASS_SPECTROMETRY: COLLISION_ENERGY 40 V
MS$FOCUSED_ION: PRECURSOR_M/Z 276
MS$FOCUSED_ION: PRECURSOR_TYPE [M+H]+
PK$SPLASH: splash10-03di-0900000000-ef8f7c2ddbdba70fe1d3
PK$NUM_PEAK: 45
PK$PEAK: m/z int. rel.int.
  44.200 2445547.0 55
  56.000 400990.5 9
  58.200 316832.0 7
  66.600 14851.5 1
  69.300 64356.5 1
  83.100 64356.5 1
  90.800 69307.0 2
  96.900 14851.5 1
  101.000 103960.5 2
  101.900 103960.5 2
  102.900 64356.5 1
  105.200 133663.5 3
  106.200 24752.5 1
  107.200 84158.5 2
  109.300 24752.5 1
  111.200 79208.0 2
  116.900 24752.5 1
  119.100 94059.5 2
  121.000 376238.0 8
  130.000 49505.0 1
  131.000 103960.5 2
  131.800 29703.0 1
  132.900 128713.0 3
  134.200 1831685.0 41
  135.000 34653.5 1
  142.100 29703.0 1
  144.100 405941.0 9
  145.200 356436.0 8
  146.100 762377.0 17
  147.000 14712886.0 328
  148.100 188119.0 4
  158.200 99010.0 2
  160.300 797030.5 18
  161.100 6316838.0 141
  162.300 44802025.0 999
  169.600 39604.0 1
  171.200 24752.5 1
  172.300 108911.0 2
  173.200 930694.0 21
  174.200 306931.0 7
  176.300 8440602.5 188
  188.300 3495053.0 78
  189.200 74257.5 2
  219.500 69307.0 2
  259.600 14851.5 1
//
